CN106518971B - Anti-obesity decapeptide CANPHELPNK - Google Patents
Anti-obesity decapeptide CANPHELPNK Download PDFInfo
- Publication number
- CN106518971B CN106518971B CN201611103465.5A CN201611103465A CN106518971B CN 106518971 B CN106518971 B CN 106518971B CN 201611103465 A CN201611103465 A CN 201611103465A CN 106518971 B CN106518971 B CN 106518971B
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- canphelpnk
- asn
- pro
- decapeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003579 anti-obesity Effects 0.000 title claims abstract description 10
- 230000005764 inhibitory process Effects 0.000 claims abstract description 20
- 238000000338 in vitro Methods 0.000 claims abstract description 10
- 230000035755 proliferation Effects 0.000 claims abstract description 6
- 210000000229 preadipocyte Anatomy 0.000 claims abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 40
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 33
- 229920001184 polypeptide Polymers 0.000 abstract description 30
- 230000000694 effects Effects 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 6
- 238000010532 solid phase synthesis reaction Methods 0.000 abstract description 3
- 238000001514 detection method Methods 0.000 abstract 1
- 238000012258 culturing Methods 0.000 description 19
- 239000001963 growth medium Substances 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 17
- 210000001789 adipocyte Anatomy 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000006285 cell suspension Substances 0.000 description 7
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 239000002699 waste material Substances 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- -1 Cys amino acid Chemical class 0.000 description 1
- PLBJMUUEGBBHRH-ZLUOBGJFSA-N Cys-Ala-Asn Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O PLBJMUUEGBBHRH-ZLUOBGJFSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- RRVCZCNFXIFGRA-DCAQKATOSA-N Leu-Pro-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O RRVCZCNFXIFGRA-DCAQKATOSA-N 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- AJCRQOHDLCBHFA-SRVKXCTJSA-N Pro-His-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O AJCRQOHDLCBHFA-SRVKXCTJSA-N 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses an anti-obesity decapeptide CANPHELPNK, the amino acid sequence of the polypeptide is shown as follows: Cys-Ala-Asn-Pro-His-Glu-Leu-Pro-Asn-Lys, abbreviated CANPHELPNK, molecular weight 1122.27, purity 97.55%. The polypeptide of the invention is synthesized by a solid phase synthesis method by using a polypeptide synthesizer. Through in vitro mouse preadipocyte 3T3-L1 proliferation inhibition activity detection, the polypeptide of the invention has certain inhibition effect on 3T3-L1 within the range of 0.125-2 mg/mL. The in vitro proliferation inhibition rate of 3T3-L1 at 2 mg/mL was 59.51%. The invention provides a synthetic polypeptide with potential in vitro anti-obesity activity, which can be applied to the field of biological pharmacy.
Description
Technical Field
The invention belongs to the field of biological pharmacy, and particularly relates to anti-obesity decapeptide and application thereof.
Background
Bioactive peptides are specific protein fragments that have a positive effect on the function or state of the body and ultimately affect the health of the body. The superiority of small molecule peptide fragments over proteins is mainly reflected in: is easier to be absorbed and utilized by human body; the activity is high, and the special physiological effect can be exerted under a smaller concentration; small molecular weight, easy modification and reconstruction, and can be synthesized by artificial chemistry, etc. Compared with single amino acid, the small molecule peptide has the advantages of no comparable amino acid in absorption channel and absorption speed besides special physiological activity. It has been proved that the small intestine of human body has special oligopeptide absorption channel, and the protein ingested by human body is hydrolyzed by various digestive enzymes and absorbed mainly in the form of oligopeptide. Many researches show that bioactive peptides from various sources have multiple functions of resisting oxidation, resisting tumors, inhibiting bacteria, reducing blood pressure, reducing blood sugar and the like, and become hot spots for developing biological medicines and health care products. Obesity increases the risk of atherosclerosis, coronary heart disease, hypertension, diabetes, gout, fatty liver, and other diseases. Therefore, the development and research of safe and harmless bioactive peptides with weight-reducing and lipid-lowering effects become important. At present, the polypeptide with the functions of losing weight and reducing fat comprises liraglutide, weever active peptide, silkworm pupa peptide and the like.
Disclosure of Invention
The invention selects mouse preadipocyte 3T3-L1 as a research object, and uses MTT method to determine the in vitro inhibitory activity of synthetic peptide. The invention aims to provide a synthetic polypeptide with in vitro anti-obesity activity, which can be applied to the field of biological pharmacy.
The synthesized anti-obesity decapeptide is abbreviated as CANPHELPNK, has a molecular weight of 1122.27, and has a sequence as follows: Cys-Ala-Asn-Pro-His-Glu-Leu-Pro-Asn-Lys. Wherein,
Cys represents the corresponding residue of an amino acid with the English name Cystein and the Chinese name Cysteine;
Ala represents the corresponding residue of the amino acid with the English name Alanine and the Chinese name Alanine;
Asn represents the corresponding residue of an amino acid named asaragine in english and Asparagine in chinese;
pro represents the corresponding residue of an amino acid having the English name Proline and the Chinese name Proline;
His represents the corresponding residue of an amino acid known by the English name Histidine and the Chinese name Histidine;
glu represents the corresponding residue of the amino acid known by the English name Glutamic acid and the Chinese name Glutamic acid;
Leu represents the corresponding residue of the amino acid named Leucine in England and Leucine in Chinese;
Pro represents the corresponding residue of an amino acid having the English name Proline and the Chinese name Proline;
Asn represents the corresponding residue of an amino acid named asaragine in english and Asparagine in chinese;
Lys represents the corresponding residue of an amino acid with the English name Lysine and the Chinese name Lysine.
The amino acid sequence of the invention adopts a standard Fmoc scheme, and a reasonable polypeptide synthesis method is realized by screening resin. The C-terminal carboxyl group of the target polypeptide is covalently linked to an insoluble polymeric resin, and then the amino group of the amino acid is used as a starting point to react with the carboxyl group of another molecule of amino acid to form a peptide bond. The process is repeated continuously to obtain the target polypeptide product. And after the synthesis reaction is finished, removing the protecting group, and separating the peptide chain from the resin to obtain the target product. Polypeptide synthesis is a process of repeated addition of amino acids, and the solid phase synthesis sequence is synthesized from the C-terminus to the N-terminus.
the invention uniformly mixes the synthetic polypeptide with the final concentration of 0.125-2 mg/mL and 3T3-L1, incubates for 48 h, and detects by an MTT method that the inhibition rate of the fat cells reaches 32.63% -59.51%, thus the invention can be applied in the field of biological medicine.
When the concentration of the decapeptide CANPHELPNK is 2 mg/mL, the in vitro proliferation inhibition rate of the decapeptide CANPHELPNK to 3T3-L1 is 59.51%.
Compared with the prior art, the invention has the following advantages and technical effects:
the peptide is synthesized for the first time, and the in vitro adipocyte proliferation inhibition activity of the synthesized polypeptide is detected by adopting an MTT method, wherein the synthesized polypeptide has certain adipocyte inhibition capacity.
Drawings
FIG. 1a is an HPLC plot of the synthetic polypeptide Cys-Ala-Asn-Pro-His-Glu-Leu-Pro-Asn-Lys.
FIG. 1b is an MS picture of the synthetic polypeptide Cys-Ala-Asn-Pro-His-Glu-Leu-Pro-Asn-Lys.
FIG. 2 is a bar graph of the inhibitory activity of the synthetic polypeptide Cys-Ala-Asn-Pro-His-Glu-Leu-Pro-Asn-Lys on adipocytes 3T 3-L1.
Detailed Description
The present invention is further illustrated by the following specific examples, but the scope of the invention is not limited thereto.
Solid phase synthesis of polypeptides
18Selecting high molecular resin (Zhongji Biochemical Co., Ltd.), connecting the carboxyl of Lys with a resin in a covalent bond mode according to the characteristics of an amino acid sequence Cys-Ala-Asn-Pro-His-Glu-Leu-Pro-Asn-Lys, then carrying out a shrinkage reaction on the amino of Asn and the carboxyl of Lys, adding the amino of Pro, Pro and the carboxyl of Asn for reaction, sequentially adding amino acid from right to left, adding the last Cys amino acid, and cutting off the resin to obtain the target polypeptide.
In vitro inhibitory Activity of synthetic Polypeptides
The growth inhibitory effect of the peptide fraction on 3T3-L1 was analyzed by MTT colorimetry. The specific operation steps are as follows:
1) taking cells in logarithmic growth phase, digesting with 0.25% (volume) trypsin-EDTA digestive juice, adding a corresponding complete culture medium to stop digestion and resuspending the cells, counting a blood cell plate, adjusting the concentration of cell suspension to 5 × 10 4/mL, adding the cell suspension into a 96-well plate, adding 100 μ L of each well, and culturing in a constant-temperature CO 2 incubator at 37 ℃;
2) after culturing for 24 hours, adhering the cells to the wall, sucking out waste culture solution, adding a fresh complete culture medium with a final volume of 200 mu L and containing samples to be detected with different concentrations, and culturing in a constant-temperature CO 2 incubator at 37 ℃ by taking the complete culture medium as a negative control;
3) Sucking out the liquid medicine after 48 hours, washing the plate for 2 times by using PBS, and adding 20 mul of 5 mg/mL MTT solution and 180 mul of fresh complete culture medium; continuously culturing in a CO2 incubator at the constant temperature of 37 ℃;
4) after 4 h, discarding the culture solution containing MTT, adding 150 mul DMSO, oscillating for 15 min on a micro oscillator, measuring the optical density value at the 490nm wavelength and calculating the inhibition rate:
The adipocyte growth inhibition ratio (%) = ((control OD-blank OD) - (administration OD-blank OD))/((control OD-blank OD)) × 100.
Application example 1
Adding adipocyte 3T 3-L1100 mu L cell suspension (5 multiplied by 10 4/mL) into a 96-well plate, culturing in a CO 2 incubator at constant temperature of 37 ℃, adhering the cells after 24 hours, sucking out waste culture solution, adding fresh complete culture medium of a polypeptide sample of 125 mu g/mL with the final volume of 100 mu L, culturing in a CO 2 incubator at constant temperature of 37 ℃ by taking the complete culture medium as a negative control, sucking out liquid medicine after 48 hours, washing the plate with PBS for 2 times, adding 20 mu L of 5 mg/mL MTT solution and 180 mu L of fresh complete culture medium, continuously culturing in a CO 2 incubator at constant temperature of 37 ℃, discarding culture solution containing MTT density value after 4 hours, adding 150 mu L DMSO, oscillating for 15 min on a micro-oscillator, measuring light at 490nm wavelength and calculating the inhibition rate, wherein the inhibition rate of polypeptide of 125 mu g/mL to adipocyte 3-1 is 32.63%.
Application example 2
Adding adipocyte 3T 3-L1100 [ mu ] L cell suspension (5 multiplied by 10 4/mL) into a 96-well plate, culturing in a CO 2 incubator at constant temperature of 37 ℃, adhering the cells after 24 hours, sucking out waste culture solution, adding a fresh complete culture medium of a polypeptide sample of 250 [ mu ] g/mL with the final volume of 100 [ mu ] L, culturing in a CO 2 incubator at constant temperature of 37 ℃ by taking the complete culture medium as a negative control, sucking out liquid medicine after 48 hours, washing the plate with PBS for 2 times, adding 20 [ mu ] L of 5 mg/mL MTT solution and 180 [ mu ] L of the fresh complete culture medium, continuously culturing in a CO 2 incubator at constant temperature of 37 ℃, discarding culture solution containing MTT density value after 4 hours, adding 150 [ mu ] L DMSO, oscillating for 15 min on a micro-oscillator, measuring light at 490nm wavelength and calculating the inhibition rate, wherein the inhibition rate of the polypeptide of 250 [ mu ] g/mL to adipocyte 3-1 is 42.28%.
Application example 3
Adding adipocyte 3T 3-L1100 [ mu ] L cell suspension (5 multiplied by 10 4/mL) into a 96-well plate, culturing in a CO 2 incubator at constant temperature of 37 ℃, adhering the cells after 24 hours, sucking out waste culture solution, adding a fresh complete culture medium of a polypeptide sample of 500 [ mu ] g/mL with the final volume of 100 [ mu ] L, culturing in a CO 2 incubator at constant temperature of 37 ℃ by taking the complete culture medium as a negative control, sucking out liquid medicine after 48 hours, washing the plate with PBS for 2 times, adding 20 [ mu ] L of 5 mg/mL MTT solution and 180 [ mu ] L of the fresh complete culture medium, continuously culturing in a CO 2 incubator at constant temperature of 37 ℃, discarding culture solution containing MTT after 4 hours, adding 150 [ mu ] L, oscillating DMSO for 15 min on a micro-oscillator, measuring light at the wavelength of 490nm and calculating the inhibition rate, wherein the inhibition rate of the polypeptide of 500 [ mu ] g/mL on adipocyte 3-L1 is 46.1%.
application example 4
Adding adipocyte 3T 3-L1100 [ mu ] L cell suspension (5 multiplied by 10 4/mL) into a 96-well plate, culturing in a CO 2 incubator at constant temperature of 37 ℃, adhering the cells after 24 hours, sucking out waste culture solution, adding a fresh complete culture medium of a polypeptide sample of 1000 [ mu ] g/mL with the final volume of 100 [ mu ] L, culturing in a CO 2 incubator at constant temperature of 37 ℃ by taking the complete culture medium as a negative control, sucking out liquid medicine after 48 hours, washing the plate with PBS for 2 times, adding 20 [ mu ] L of 5 mg/mL MTT solution and 180 [ mu ] L of the fresh complete culture medium, continuously culturing in a CO2 incubator at constant temperature of 37 ℃, discarding culture solution containing MTT density value after 4 hours, adding 150 [ mu ] L DMSO, oscillating for 15 min on a micro-oscillator, measuring light at 490nm wavelength and calculating the inhibition rate, wherein the inhibition rate of the polypeptide of 1000 [ mu ] g/mL to adipocyte 3-1 is 48.36%.
application example 5
Adding adipocyte 3T 3-L1100 [ mu ] L cell suspension (5 multiplied by 10 4/mL) into a 96-well plate, culturing in a CO 2 incubator at constant temperature of 37 ℃, adhering the cells after 24 hours, sucking out waste culture solution, adding a fresh complete culture medium of a polypeptide sample with the final volume of 100 [ mu ] L of 2000 [ mu ] g/mL, culturing in a CO2 incubator at constant temperature of 37 ℃ by taking the complete culture medium as a negative control, sucking out liquid medicine after 48 hours, washing the plate for 2 times by PBS, adding 20 [ mu ] L of 5 mg/mL MTT solution and 180 [ mu ] L of the fresh complete culture medium, continuously culturing in a CO 2 incubator at constant temperature of 37 ℃, discarding culture solution containing MTT density value after 4 hours, adding 150 [ mu ] L DMSO, oscillating for 15 min on a micro-oscillator, measuring light at 490nm wavelength and calculating the inhibition rate, wherein the inhibition rate of the polypeptide with the density of 2000 [ mu ] g/mL to adipocyte 3-1 is 59.51%.
SEQUENCE LISTING
<110> university of southern China's science
<120> an anti-obesity decapeptide CANPHELPNK
<130>
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 10
<212> PRT
<213> Artificial sequence
<400> 1
Cys Ala Asn Pro His Glu Leu Pro Asn Lys
1 5 10
Claims (2)
1. an anti-obesity decapeptide CANPHELPNK, characterized in that the amino acid sequence of the decapeptide CANPHELPNK is Cys-Ala-Asn-Pro-His-Glu-Leu-Pro-Asn-Lys; when the concentration of the decapeptide CANPHELPNK is 0.125-2 mg/mL, the in vitro proliferation inhibition rate of the preadipocyte 3T3-L1 is 32.63% -59.51%.
2. The anti-obesity decapeptide CANPHELPNK according to claim 1, wherein the in vitro proliferation inhibition rate of the decapeptide CANPHELPNK to 3T3-L1 at a concentration of 2 mg/mL is 59.51%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611103465.5A CN106518971B (en) | 2016-12-05 | 2016-12-05 | Anti-obesity decapeptide CANPHELPNK |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611103465.5A CN106518971B (en) | 2016-12-05 | 2016-12-05 | Anti-obesity decapeptide CANPHELPNK |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106518971A CN106518971A (en) | 2017-03-22 |
| CN106518971B true CN106518971B (en) | 2019-12-10 |
Family
ID=58354826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611103465.5A Active CN106518971B (en) | 2016-12-05 | 2016-12-05 | Anti-obesity decapeptide CANPHELPNK |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106518971B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109081862A (en) * | 2018-06-07 | 2018-12-25 | 华南理工大学 | The anti-obesity tetrapeptide PQTR of one kind and its application |
| CN108676073B (en) * | 2018-06-07 | 2021-10-26 | 华南理工大学 | Anti-obesity decapeptide LLVVYPWTQR and application thereof |
| CN114315965B (en) * | 2021-12-22 | 2023-05-12 | 华南理工大学 | Anti-obesity peptides and uses thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5525705A (en) * | 1995-01-31 | 1996-06-11 | Eli Lilly And Company | Anti-obesity proteins |
| US5532336A (en) * | 1995-01-31 | 1996-07-02 | Eli Lilly And Company | Anti-obesity proteins |
| JP2005220074A (en) * | 2004-02-05 | 2005-08-18 | Fancl Corp | Inhibitor of fat-cell differentiation |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101669140B1 (en) * | 2015-04-28 | 2016-10-26 | (주)케어젠 | Peptides having Anti-obesity and Anti-Diabetes Effects and Use Thereof |
| CN104840943A (en) * | 2015-05-05 | 2015-08-19 | 中国农业科学院作物科学研究所 | Application of Lunasin polypeptide in aspect of preparing substance with weight-reducing activity |
| CN104829705B (en) * | 2015-05-06 | 2017-11-14 | 广东省生物资源应用研究所 | The leptin activity peptide of one C spiral region mutation and its encoding gene and application |
-
2016
- 2016-12-05 CN CN201611103465.5A patent/CN106518971B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5525705A (en) * | 1995-01-31 | 1996-06-11 | Eli Lilly And Company | Anti-obesity proteins |
| US5532336A (en) * | 1995-01-31 | 1996-07-02 | Eli Lilly And Company | Anti-obesity proteins |
| JP2005220074A (en) * | 2004-02-05 | 2005-08-18 | Fancl Corp | Inhibitor of fat-cell differentiation |
Non-Patent Citations (1)
| Title |
|---|
| 藻蓝蛋白酶解条件优化及产物抑制肥胖相关酶活性的研究;周丽丽;《中国优秀硕士学位论文全文数据库》;20150215(第2期);1-73 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106518971A (en) | 2017-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109400678B (en) | Stichopus japonicus-derived antioxidant and DPP-IV inhibitory active peptide | |
| CN106699846B (en) | Anti-obesity undecapeptide NALKCCHSCPA | |
| CN108676073B (en) | Anti-obesity decapeptide LLVVYPWTQR and application thereof | |
| CN104710511A (en) | Iron chelating peptide derived from hairtail fish protein and preparation method and application thereof | |
| CN106518971B (en) | Anti-obesity decapeptide CANPHELPNK | |
| CN111269290B (en) | Preparation method of sturgeon anti-inflammatory peptide | |
| CN106749524B (en) | Anti-obesity heptapeptide NPVWKRK | |
| CN105237624B (en) | A kind of heptapeptide EMLQPPL and its application | |
| CN105131089B (en) | A kind of tridecanoic peptide and its application | |
| CN112745380B (en) | Bioactive peptide with amino acid structure RAGLQFPVGRVH, and preparation method and application thereof | |
| CN109081862A (en) | The anti-obesity tetrapeptide PQTR of one kind and its application | |
| CN106749533B (en) | Anti-obesity heptadecapeptide LNNPSVCDCDCMMKAAR | |
| CN113072621B (en) | Yak bone antihypertensive peptide and preparation method and application thereof | |
| CN105175496B (en) | A kind of heptapeptide PGKPLFL and its application | |
| CN106084011B (en) | A kind of dodecapeptide VPGTPKNLDSPR and its application | |
| CN110655553B (en) | ACE inhibitory peptide derived from sesame, preparation method and application thereof in preparation of antihypertensive drugs | |
| CN105153283B (en) | A kind of octapeptide SCCSCDED and its application | |
| CN112661830A (en) | Bioactive peptide with amino acid structure AIRNDEELNKLLGR, and preparation method and application thereof | |
| CN108101960B (en) | Polypeptide molecule with ACE inhibitory activity and anti-tumor effect and preparation method thereof | |
| CN110724179A (en) | Anti-tumor polypeptide and preparation method and application thereof | |
| RU2078769C1 (en) | Peptide fragment showing biological activity of insulin | |
| CN110467667A (en) | A kind of anti-tumor activity peptide and its application | |
| CN112646023B (en) | Bioactive peptide with amino acid structure VNVVPTFGKKKGP, and preparation method and application thereof | |
| CN113880916B (en) | Yak skin antioxidant polypeptide and preparation method and application thereof | |
| CN112794881B (en) | Anti-liver cancer tridecapeptide NKSGTYSNDDLSH and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |